Avinger (AVGR) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.

Avinger's stock was trading at $1.0850 at the beginning of 2023. Since then, AVGR shares have decreased by 48.1% and is now trading at $0.5630.
View the best growth stocks for 2023 here.

Avinger saw a drop in short interest in May. As of May 15th, there was short interest totaling 317,000 shares, a drop of 48.6% from the April 30th total of 616,600 shares. Based on an average daily trading volume, of 241,400 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.0% of the company's stock are short sold.
View Avinger's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AVGR earnings forecast.

Avinger, Inc. (NASDAQ:AVGR) released its earnings results on Wednesday, March, 15th. The medical device company reported ($0.70) earnings per share for the quarter. The medical device company had revenue of $2 million for the quarter. Avinger had a negative net margin of 207.02% and a negative trailing twelve-month return on equity of 530.21%.

Shares of Avinger reverse split before market open on Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Organigram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).

(AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Avinger's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (4.38%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski, Mark Weinswig and Nabeel Paul Subainati.
View institutional ownership trends.

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVGR stock can currently be purchased for approximately $0.56.

Avinger (NASDAQ:AVGR) has a market capitalization of $6.02 million and generates $8.27 million in revenue each year. The medical device company earns $-17,620,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696.